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Haemophilus influenzae type b (Hib) still causes a sub-
stantial number of deaths among children in developing
countries, despite the availability of effective conjugate vac-
cines. A major obstacle in developing a Hib vaccine has
been limited awareness about the impact of Hib disease. A
tool was developed to estimate the national rates of Hib
meningitis and pneumonia by assessing retrospective local
data over 7 to 10 days. Data from 11 countries in Africa, the
Middle East, and Asia were studied and showed rates of
Hib meningitis from >50 cases per 100,000 children >5
years in Ghana and Uganda to <15 per 100,000 in Iran,
Jordan, and Uzbekistan. Results were affected by the qual-
ity of available data. The Hib rapid assessment tool can be
useful to countries that desire a timely assessment of Hib
disease rates. 
A
mong infants and young children, Haemophilus
influenzae type b (Hib) is the leading cause of bacter-
ial meningitis deaths and the second leading cause of bac-
terial pneumonia deaths worldwide and accounts for
approximately 400,000 deaths of children each year (1,2).
These deaths are preventable through Hib conjugate vac-
cines (1). In the United States, Hib conjugate vaccines were
first introduced into the routine immunization program for
infants in 1990. Subsequently, most industrialized, western
countries have introduced these vaccines. Hib conjugate
vaccines, however, are still not widely used in developing
countries, where the greatest rates of Hib-related disease
and deaths occur. Before 2002, only children in 2 of 51
countries with an infant death rate >70 per 1,000 live births
were routinely vaccinated against Hib (Figure 1).
The major obstacles to introducing Hib conjugate vac-
cines into developing countries have been their cost and
the population’s limited awareness about the impact of Hib
disease. The Hib conjugate vaccine, even after a decade of
use, is still expensive, costing approximately $U.S. 2.50
per dose, and thus, external financial resources are needed
to procure the vaccine in most developing countries. Since
1999, the Global Alliance for Vaccines and Immunization
(GAVI) through the Vaccine Fund has provided a mecha-
nism of financing Hib conjugate vaccines for 5 years to the
75 poorest countries (http://www.vaccinealliance.org/
home/index.php). Despite this opportunity, few countries
initially requested the Hib vaccine through GAVI, partly
because of limited awareness about the rate of Hib disease. 
Diagnosing Hib disease is difficult; Hib primarily caus-
es meningitis and pneumonia, two common syndromes
often treated empirically. To diagnose Hib meningitis,
lumbar punctures must be performed and cerebrospinal
fluid rapidly processed in a microbiologic laboratory with
the technical capability and supplies to culture Hib. Hib
pneumonia is even more difficult to diagnose. Although
blood cultures are highly specific for Hib, they have a sen-
sitivity of 20%, thus allowing the role of Hib as a cause of
pneumonia to be underestimated (3,4). 
Several methods have been used to define the rate of
Hib disease in developing countries. Randomized, con-
trolled trials of the Hib conjugate vaccine in The Gambia,
which looked at radiographic evidence of pneumonia as a
study endpoint, showed that approximately 20% of consol-
idated pneumonia (diagnosed by chest x-ray) is prevented
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(5). In Chile, a retrospective analysis of pneumonia after a
randomized, controlled trial of Hib vaccine showed a 22%
reduction in consolidation or pleural effusion in the group
that received vaccine (6). Despite the quality of the data
produced, such trials are too expensive, time-consuming,
and complex to be widely used to measure Hib disease. A
more widely used method to measure Hib disease has been
population-based laboratory surveillance for Hib meningi-
tis (7). Such surveillance, although dependent on the rate
of lumbar punctures and laboratory quality, can produce
reliable data on the incidence rate of Hib meningitis, which
can be compared across countries. Population-based sur-
veillance for meningitis, however, requires at least a year
to produce results and does not give an estimate of Hib
pneumonia.
Alternatives to these longitudinal, time-consuming,
resource-intense methods of measuring Hib disease are
being sought, particularly for use in regions of the world,
such as Africa, where studies have consistently shown high
rates of Hib disease (8–12). In countries in these regions,
more limited data on the local rate of Hib disease may be
adequate to allow evidence-based decisions about intro-
ducing Hib vaccine and to provide a basis for national
advocacy for, and commitment to, such decisions. 
On the basis of these considerations, we created a rapid
assessment tool to measure the national rate of severe Hib
disease. We discuss the methods used in the rapid assess-
ment tool and its results in the first 11 countries where it
was used.
Methods
Logistics
Requests for Hib rapid assessments were made by
national ministries of health. The Hib rapid assessment
tool was usually completed in 7 to 10 days. The assessment
teams consisted of local representatives from the ministry
of health and one or two consultants familiar with the tool.
National data relevant to the tool was collected by review-
ing national health statistics and medical literature, focus-
ing on national or regional journals. The assessment often
included several days in the capital city reviewing avail-
able data and working with the ministry of health. Most of
the assessment involved collecting, evaluating, and syn-
thesizing existing data from hospitals. Data were entered
into standardized spreadsheets that assist in the calculation
of the national disease impact. The assessment often ended
with a meeting to discuss the findings with key persons in
the ministry of health and leading pediatricians.
The tool uses two different, complementary methods to
estimate Hib rates. The first one works from the “bottom
up,” beginning with a local estimate of Hib meningitis
incidence rates; the second works from the “top down,”
starting with the country’s under-5 mortality rate, which is
the number of children per 1,000 live births who die before
their fifth birthday. 
Meningitis Incidence Rate Method 
This method uses retrospective data to calculate an inci-
dence rate of Hib meningitis, from which the annual num-
bers of cases of and deaths attributable to Hib meningitis
and pneumonia are estimated. The first step for this
method is selecting an appropriate site where the incidence
of Hib meningitis can be accurately calculated. The ideal
site is a region of the country where the catchment popula-
tion of a hospital or a few hospitals can be well defined,
where most children with meningitis go to these hospitals,
and where the private sector rarely uses the Hib vaccine. In
addition, physicians in these hospitals should routinely
perform lumbar punctures on children with suspected
meningitis, and the hospitals should have laboratories that
culture H. influenzae and conduct cytologic tests on cere-
brospinal fluid. Although few laboratories in our assess-
ments performed serotyping, we assumed that, in the
absence of vaccination, all H. influenzae in cerebrospinal
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Figure 1. Global status of countries
using Hib conjugate vaccine in their
national immunization program in 2001
(J. Wenger, WHO, unpub. data). fluid was caused by type b (Hib), which is consistent with
available studies (13,14). 
Calculating Hib meningitis incidence rate begins by
counting the number of cases of culture-confirmed menin-
gitis in children <5 years of age during a defined period in
a defined catchment population (Figure 2). The percentage
of culture-confirmed meningitis caused by Hib is then cal-
culated. Cerebrospinal fluid samples from neonates are
excluded because Hib is very rare in the first month of life
(15). Next, the number of purulent cerebrospinal fluid
samples during the same period is counted. For the purpos-
es of this tool, purulence is defined in a way that increases
the specificity for bacterial meningitis: visible turbidity,
>100 leukocytes/mm3, or 10–99 leukocytes/mm3 with glu-
cose <40 mg/dLand protein >100 mg/dL. The culture-con-
firmed cases are excluded, which leaves a count of
culture-negative, purulent cerebrospinal fluid samples.
The tool assumes that these are bacterial in origin, and the
number ascribed to Hib is calculated by applying the same
percentage of culture-confirmed meningitis caused by Hib
to the culture-negative, purulent specimens. The rationale
for this step is that a certain percentage of Hib meningitis
cases may not be culture-confirmed because of prior
antimicrobial drug use or laboratory-related factors. The
number of culture-confirmed Hib cases and estimated cul-
ture-negative Hib cases is added. Then this number is
inflated by a factor on the basis of information from local
pediatricians to account for children with suspected
meningitis who did not get a lumbar puncture. The number
of children <5 years of age in the catchment region of the
hospitals is used as the denominator to calculate the Hib
meningitis incidence rate.
In the last step, the total number of children <5 years of
age in the country is used to estimate the annual number of
cases of Hib meningitis in the country. By using a ratio of
five Hib pneumonia cases for each case of Hib meningitis,
which was found in two randomized studies of Hib conju-
gate vaccine, the annual number of cases of Hib pneumo-
nia is estimated (5,6). By using the case-fatality
proportions of Hib meningitis and Hib pneumonia,
obtained locally if possible, the annual number of deaths
attributable Hib in the country is also estimated. 
Under-5 Mortality Rate Method
This method starts with the birth cohort in the country
(Figure 3). To calculate the number of childhood deaths in
the country, the under-5 mortality rate is applied to the
birth cohort. The neonatal death rate, if available, is sub-
tracted from this number. Then the percentage of child-
hood deaths caused by acute respiratory illness is
estimated. This percentage is extrapolated from a study
that showed that the higher the under-5 mortality rate, the
greater percentage of deaths that are caused by respiratory
illness (16). In the next step, the percentage of all acute
respiratory illness deaths due to Hib is estimated to be
13%. This figure was obtained by subtracting the number
of respiratory deaths unlikely to be caused by Hib, during
the neonatal period and caused by measles and pertussis,
and multiplying the remaining number of respiratory
deaths by 20%, the percentage of severe pneumonia
thought to be caused by Hib (5,6,17). This calculation
yields the annual number of pneumonia deaths caused by
Hib. Then, meningitis cases and meningitis deaths are cal-
culated by using the case-fatality proportion of Hib pneu-
monia, the 5:1 Hib pneumonia:meningitis ratio, the Hib
meningitis case-fatality proportion, and the annual number
of Hib pneumonia cases. 
Review of the Rapid Assessment Tool
The tool was pilot-tested in several countries, and a
draft version was reviewed at a meeting of technical
experts convened by the World Health Organization in
October 2000. Suggested revisions to the tool made at the
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Figure 2. The meningitis incidence rate method for calculating
Haemophilus influenzae type b (Hib) disease rate by using the Hib
rapid assessment tool. White boxes are data input points and gray
boxes are disease rate estimates. 
Figure 3. The under-5 mortality rate method for calculating
Haemophilus influenzae type b (Hib) disease rate by using the Hib
rapid assessment tool. White boxes are data input points and gray
boxes are disease rate estimates.meeting were subsequently incorporated. The minutes of
this meeting (http://www.who.int/vaccines-documents/
DocsPDF01/www604.pdf), along with the completed tool
including worksheets, are available on the Internet
(http://www.who.int/vaccines-documents/DocsPDF01/
www625.pdf).
Results
The Hib rapid assessment tool has been used in 11
developing countries in sub-Saharan Africa, the Middle
East, and Asia (Tables 1 and 2). The assessment of the
meningitis incidence rate was performed most often in
smaller cities, where the denominator population could be
more easily delineated, although several assessments were
performed in larger cities, such as Alexandria, Egypt, and
Shiraz, Iran. In most countries, at least one hospital had cul-
tured H. influenzae from cerebrospinal fluid. The excep-
tions were Uzbekistan, Yemen, and Ghana. Alternative
strategies were used to estimate the incidence rate of Hib
meningitis in these countries. In Uzbekistan, where labora-
tories had been unable to culture Hib from cerebrospinal
fluid and the leukocyte counts were not being performed
properly, data from a prospective, population-based study
in Moscow, which has a very similar health care system,
were applied to the rate of lumbar punctures performed in
Uzbek children to yield an estimate of the Hib meningitis
incidence (A. Platonov, pers. comm.). In Ghana, Gram stain
results of cerebrospinal fluid, rather than culture, were used
to estimate the rate of Hib meningitis. In Yemen, data about
purulent meningitis from another hospital in the capital and
review of data from the local literature were used to esti-
mate the rate of Hib meningitis.
The percentage of culture-confirmed meningitis caused
by Hib was 33%–67%. Most hospitals were able to per-
form leukocyte counts on cerebrospinal fluid, but a few
hospitals routinely measured protein and glucose. The
incidence rate of culture-confirmed Hib meningitis varied
greatly, depending on the ability to find hospitals consis-
tently able to culture Hib from cerebrospinal fluid. Except
for a few countries (i.e., Uganda, Oman, and Kyrgyzstan),
the rates of culture-confirmed meningitis were very low,
<10 per 100,000 children <5 years of age. When we used
the rapid assessment tool, the estimated rates of Hib
meningitis tended to be several-fold higher than those
based on culture-confirmed Hib. When we used the tool,
the estimated incidence rate of Hib meningitis among chil-
dren <5 years of age was >50 cases per 100,000 children
<5 years of age in Ghana and Uganda to <15 cases in Iran,
Jordan, and Uzbekistan. The under-5 mortality rate method
yielded estimates of national Hib disease rates that were
higher than those obtained from the meningitis incidence
rate method (mean 2.8, 95% confidence interval 1.7–3.9.)
Discussion 
The Hib rapid assessment tool estimated rates of Hib
meningitis in Africa and the Middle East that were similar
to those obtained from population-based studies in the same
regions (Figure 4, 8–12,18–22). In countries in Eastern
Europe and Asia where the impact of Hib meningitis is less
well-defined, the tool yielded variable results, although
not too discrepant from rates found from prospective,
population-based surveillance performed in other countries
in the same areas (23–26). These results demonstrate that
the Hib rapid assessment tool can yield estimates of Hib
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Table 1. Results of Haemophilus influenzae type b (Hib) rapid assessment tool (meningitis incidence rate method) in 11 developing 
countries 
Country  % culture-
confirmed
a 
Unadjusted  
Hib meningitis rate
b 
Adjusted  
Hib meningitis rate
c 
Meningitis  
cases/deaths
d 
Pneumonia 
cases/deaths
d 
Ghana  NA  0  72
e  2,030/609  10,148/2,030 
Uganda  50  44  59  2,533/633  12,663/759 
Egypt  50  1  23  1,795/682  8,977/539 
Iran  67  5  7  599/12  2,994/180 
Jordan  43  6  14  107/5  534/27 
Morocco  44  6  23  689/34  3,443/172 
Oman  43
f  27  41  112/11  560/34 
Yemen  NA  0  23
f  790/245  3,950/897 
Kyrgyzstan  33  15  20  101/12  505/51 
Uzbekistan  NA  0  4
g  103/12  515/52 
Bhutan  42  6  15  16/5  80/8 
aMeningitis caused by Hib. 
bUnadjusted meningitis incidence rate is the number of culture-confirmed Hib meningitis cases per 100,000 children ?5 years of age in the study site 
without making any of the adjustments accounted for in the rapid assessment tool (see Methods).  
cAdjusted meningitis incidence rate is the number of Hib meningitis cases per 100,000 children <5 years of age in the study site, as determined by the 
rapid assessment tool (see Methods).  
dNational estimates. 
eBased on Gram stain of coccobacilli. 
fBased on literature review and use of data from hospital. 
gBased on use of data from Moscow study and rate of lumbar puncture in Uzbekistan. disease rates similar to expected rates in many countries.
Without some of the adjustments made by the tool, the inci-
dence rate of culture-confirmed Hib meningitis would have
been low in most of these countries. One strength of the
tool is that its adjustments compensate for artificial reasons
for low incidence rates of culture-confirmed Hib meningi-
tis, such as low rates of lumbar puncture and the lack of
appropriate microbiologic capacity.
While not meant to replace more rigorous and accurate
methods used to measure Hib disease, such as prospective,
population-based surveillance, the tool addresses a unique
need for countries desiring local Hib disease rate estimates
to assist them in making a decision to introduce Hib vac-
cine. The strengths of the tool in addressing this need are
that it is rapid, inexpensive, uses locally obtained data,
accounts for biases in these data that might underestimate
the true rate of Hib disease, and provides disease impact
output as the number of cases and deaths from Hib disease,
which is often more tangible to decision makers than inci-
dence rates. Moreover, the process of performing the rapid
assessment engages pediatricians and decision makers in a
dialogue about the clinical, epidemiologic, and laboratory
aspects of Hib disease and vaccine. Consequently, the Hib
rapid assessment process helps countries develop the
capacity to critically evaluate existing local data and per-
ceptions about Hib disease rates.
The Hib rapid assessment tool has several limitations.
Whereas in most countries we found hospitals that effec-
tively cultured Hib, in several countries we were unable to
find any site with demonstrated capacity to culture Hib. In
these countries, we were unable to use the meningitis inci-
dence rate method as outlined in the tool. As mentioned,
alternative strategies based on local and regional data were
used here, which might have introduced inaccuracies.
Nonetheless, the estimates of Hib impact in these countries
were similar to those observed in population-based studies
from the same regions (Figure 4).
A second limitation of the tool is that even when a hos-
pital that has cultured Hib is found, the output from the
tool using the meningitis incidence rate method will
always be constrained by the quality of the data. Although
the tool corrects for missed cases of Hib meningitis, it does
not correct completely for substantial underdiagnosis of
Hib meningitis. If clinical or microbiologic factors have
led to such underdiagnosis, this will necessarily be reflect-
ed in the rate estimates made by the tool. This limitation
was exemplified during the rapid assessment in
Kyrgyzstan, where the tool found a rate of Hib meningitis
of 20.4 per 100,000 in 1999 to 2000, a period when the
infectious disease hospital in Bishkek was involved in a
study with Aventis-Pasteur, which supplied the laboratory
with appropriate reagents and materials to isolate Hib.
From 2001 through 2002, after the study ended, the rate
obtained from tool in the same hospital decreased to 4.7
per 100,000. 
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Table 2. Results of Haemophilus influenzae type b (Hib) rapid assessment tool (under-5 mortality rate method) in 11 developing 
countries 
Country  U5MR
a  Meningitis cases/deaths
b  Pneumonia cases/deaths
b  Ratio meningitis cases U5MR:MIR
a 
Ghana  110  5,465/984  27,326/4,099  2.7 
Uganda  147  2,838/709  14,189/2,838  1.1 
Egypt  65  6,731/2558  33,657/2,019  3.7 
Iran  31.5  1,975/40  9,876/593  3.3 
Jordan  33  313/16  1,563/78  2.9 
Morocco  Not done      – 
Oman  21.5  48/15  242/14  0.43 
Yemen  105  3,085/956  15,427/956  3.9 
Kyrgyzstan  19.6
 c  125/15  625/63  1.2 
Uzbekistan  21
c  565/68  2,826/283  5.4 
Bhutan  63
c  54/18  270/27  3.4 
a U5MR, under-5 mortality rate method; MIR, meningitis incidence rate method. 
bNational estimates. 
cU5MR excludes neonatal diseases.
 
Figure 4. Comparison of incidence rates of Haemophilus influen-
zae type b (Hib) meningitis per 100,000 children <5 years of age
between the rapid assessment tool (gray bars) and prospective,
population-based laboratory surveillance (white bars), by region
(8–10,12,19–26). UAE, United Arab Emirates.A third limitation of the rapid assessment tool is that
several assumptions are incorporated into the calculations.
These assumptions, although based on the available litera-
ture, may not apply to all populations. For example, the 5:1
ratio of Hib pneumonia to meningitis, which was based on
the results of two randomized controlled vaccine trials in
The Gambia and Chile, may not apply to all parts of the
world (5,6). In countries with lower under-5 mortality
rates, the 5:1 ratio may be too high, while in countries with
high under-5 mortality rates, the 5:1 ratio may be too low.
Moreover, this ratio may vary in different parts of the
world, as suggested from the results of a recently complet-
ed Hib conjugate vaccine efficacy trial in Lombok,
Indonesia, which suggested the incidence of Hib meningi-
tis to be high and the incidence of radiographically defined
Hib pneumonia to be relatively low (27).
A fourth concern is that the under-5 mortality rate
method yielded higher estimates of Hib disease rates than
the meningitis incidence rate method. One reason for this
difference is that the neonatal death rate was not subtract-
ed from the under-5 mortality rate in most countries
(except Kyrgyzstan, Uzbekistan, and Bhutan). This omis-
sion may have led to overestimating Hib disease since
neonatal deaths account for a large proportion of childhood
deaths, but Hib deaths are rare in neonates (13). Also,
because the under-5 mortality rate method starts with
pneumonia deaths and works backwards to meningitis
cases, more assumptions are made in the last estimate.
Therefore, in reconciling the estimates obtained from the
two methods, the meningitis prevalence may be more
accurate than the meningitis incidence rate method, while
estimation of the pneumonia incidence may have an accu-
racy in between those obtained from the two methods. 
The results of the Hib rapid assessment tool need to be
interpreted in light of its limitations and the validity of its
assumptions critically evaluated in each country where it is
used, particularly in regions, such as Asia, where the impact
of Hib disease is still uncertain. Nonetheless, the tool has
been useful to some countries in deciding whether to adopt
Hib vaccine into their national immunization programs. Of
the countries we studied, three (Ghana, Uganda, and Oman)
introduced Hib vaccine, and three others (Bhutan,
Kyrgyzstan, and Yemen) requested Hib vaccine on their ini-
tial application to GAVI. Subsequent to the assessments in
these countries, the tool has been used in several other
developing countries that were considering the introduction
of Hib vaccine (Western Pacific Islands [28], Albania,
Thailand, Nepal, and Sudan). Several countries (Uganda,
Albania, and Egypt) have used results of the rapid assess-
ment tool in cost-effectiveness analyses of Hib vaccine
introduction. As more developing countries consider Hib
vaccination programs, estimating the local impact of Hib
disease will continue to be an important part of the effort to
introduce and sustain Hib vaccination programs. The expe-
rience with measuring Hib disease rates, including the rapid
assessment tool, might also provide a valuable base for con-
sidering the introduction of other new vaccines, including
pneumococcal and meningococcal conjugates.
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